Denmark Sweden Norway Finland  Genzyme Finland HomeYhteystiedotGenzyme Corporate Home
GENZYME YRITYKSENÄ
TERAPIA-ALUEET
TUOTTEET
Genzyme 
Genzyme on maailman johtavimpia bioteknologian yrityksiä, ja sen tavoitteena on parantaa vakavia sairauksia potevien potilaiden elämää. Lue lisää tästä >
 
LEHDISTöTIEDOTTEET
Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Fourth Annual Patient Advocacy Leadership (PAL) Awards

CAMBRIDGE, Mass. - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced its support of International Rare Disease Day with a series of initiatives meant to call attention to rare diseases as an important public health issue and to improve rare disease education, research, and treatment. Observed annually on the last day of February, Rare Disease Day is an international awareness campaign organized by the patient organization EURORDIS and supported by hundreds of other patient organizations around the world.
Lisää >
Genzyme to Invest Million in Framingham, Mass. Site to Expand Manufacturing Capacity for Fabrazyme®

Tuesday, October 15, 2013 8:00 am EDT
Dateline: CAMBRIDGE, Mass.

Public Company Information:
NYSE:SNY
US80105N2045

BOURSE:SAN
FR0000120578

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that it is investing million to build a new downstream processing facility for Fabrazyme® (agalsidase beta). The new plant, which will be located adjacent to the new Fabrazyme cell culture manufacturing site in Framingham, Massachusetts, will significantly expand purification capacity to support anticipated growth in global demand over the coming years.
Lisää >
Genzyme’s Multiple Sclerosis Franchise Featured at ECTRIMS

- 18 Platform and Poster Presentations Provide Deeper Insight Into the Clinical Development Programs for Aubagio® and Lemtrada™ -  Cambridge, Mass. – September 26, 2013 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) announced today that new data from its Aubagio® (teriflunomide) and Lemtrada™ (alemtuzumab) clinical development programs will be presented during the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18th Annual Conference of Rehabilitation in MS (RIMS) to be held in Copenhagen, Denmark, October 2-5.
Lisää >
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)

- Follows Recent European Commission Approval of Multiple Sclerosis Treatment Aubagio® (teriflunomide) - Approvals Set the Stage for Launches Throughout EU and Strongly Position Genzyme as a Committed Partner to the MS Community -

Paris, France – September 17, 2013
– Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Commission has granted marketing authorization for Lemtrada™. This follows the August 30th approval of Aubagio®. The company intends to begin launching both products in the EU soon.
Lisää >
GENZYME
BIOSURGERY
GENZYME
MAAILMANLAA-
JUISESTI
GENZYME
CORPORATION
 

Terms and Conditions Privacy Policy © 2008 Genzyme. All Rights Reserved. Webmaster